MARKET WIREYahoo Finance • 22h ago
Should Value Investors Buy Henry Schein (HSIC) Stock?Yahoo Finance report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
Why HSIC Stock surged +2.05% Today — RQD Quant Desk Flash
$86.62 +2.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $86.78
Henry Schein Inc. (HSIC) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $9.46B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HSIC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HSIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Henry Schein Inc. (NASDAQ: HSIC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $86.62 (+2.05% 1D, market cap $9.46B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, HSIC ranks #180 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HSIC compare to OSCR and CAI in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), HSIC carries a Roarable D+ (58/100 RQD), trailing P/E of 23.0x, gross margin of 31.1%, and ROIC of 11.2%. By comparison, OSCR (Oscar Health Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.37B) and CAI (Caris Life Sciences Inc.) posts a B grade (73/100 RQD, P/E N/A, ROIC 4.4%, cap $9.70B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HSIC?
▼
Per HSIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001000228), Henry Schein Inc. generated $13.18B in revenue (+4.0% YoY), $419.0M in net income, and $118.7M in free cash flow against $11.21B in total assets and $2.89B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $86.78 (+0.18%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HSIC)Realized 20D OHLCV Swing Band: ±4.8%
Deterministic 5-Pillar Attribution (58/100 Composite)
🔍 WHY HSIC SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (24% of score)
Altman Z-Score 2.81 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (21% of score)
FRED Regime × Technicals: 81% of 52W Range • RSI-14 at 47.5 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Cash Engine Quality9/20 pts (-11 pt drag)
Capital intensity & 5% operating margin leave 11 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$85.56-0.6% Next Q
50
Q2 (-2Q)Grade C-$85.01-0.1% Next Q
53
Q3 (-1Q)Grade C$84.96+2% Next Q
55
CurrentGrade D+$86.62+0% Hist 90D α
58
Trajectory: C- (50) → D+ (58)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the HSIC Bull Thesis Could Fail
Even with a 58/100 (D+) score, HSIC faces multiple-compression risk if 23.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) — any gross margin slip below 28.6% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($86.33) or 200D SMA ($81.17) invalidates the momentum regime and cuts Target Base ($86.62) toward Bear Floor ($67.56).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HSIC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HSIC Beats Next Quarter EPS Consensus (Dec 26, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HSIC Stock surged +2.05% Today — RQD Quant Desk Flash
Henry Schein Inc. (HSIC) surged +2.05% to $86.62, trading at 81% of its 52-week range ($63.04 – $92.18). Stretched risk/reward at 23x P/E (11% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 81% of its 52-week range ($63.04 – $92.18) with RSI-14 at 47.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.8% around $86.62 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 31.1% gross margin and $118.7M annual free cash flow.
Live HSIC Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Henry Schein to Report Q3 Earnings: Here's What You Should KnowTradingView report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Henry Schein (HSIC), What Is Behind The Fresh Attention Now?Yahoo Finance report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Unpacking Q2 Earnings: Henry Schein (NASDAQ:HSIC) In The Context Of Other Dental Equipment & Technology StocksThe Globe and Mail report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
RISK WATCHTradingView • 1d ago
Henry Schein, Inc. Stock 12‑Month Price Target Cut to $97.27, Implies 16% UpsideTradingView report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall Street • 1d ago
Why Henry Schein (HSIC) Is Getting Attention NowSimply Wall Street report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Henry Schein, Inc. Estimates – NASDAQ:HSICTradingView report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
Henry Schein (HSIC) Could Be 16% Undervalued On Higher Margin Growth StorySimply Wall St report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 23h ago
Global Orthodontic Braces Market Size, Share, and Forecast Report 2026-2031 Featuring Profiles of Dentsply Sirona, Align Technology, Straumann, Envista, 3M, Henry Schein, and American OrthodonticsCapitalize on clear aligners, adult orthodontics, AI-driven personalization and direct-to-consumer care through targeted innovation and digital accessDublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Orthodontic Braces Market (
RISK WATCHChartMill • 1d ago
S&P 500 Premarket Movers Nov. 2, 2026: IDEXX and Fox Gain, Lumentum and T-Mobile FallIDEXX Laboratories and Fox Corp. led S&P 500 premarket gainers on Nov. 2, 2026, while Lumentum and T-Mobile led the decliners.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSIC)
- ✓Walkthrough of HSIC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HSIC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.27%⚡ TESTING RESISTANCE
2026-11-03O $86.44H $86.62L $84.88C $86.62VOL 1.20M
RES: $86.59SUP: $78.03SMA50: $86.33SMA200: $81.17
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HSIC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
16.8%/yr Implied 5Y Growth
vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on HSIC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HSIC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HSIC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSIC)
Health Care Rank #180 of 1015
⚔️ OSCR vs HSIC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HSIC vs. OSCR, CAI, MOH, GRAL)
Industry: Medical Specialities (41 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Henry Schein Inc. (HSIC) ranks #180 by composite RQD confidence (58/100, grade D+) and #115 by equity capitalization ($9.46B). Within this direct 5-issuer industry benchmark cohort, MOH leads on earnings valuation at 22.0x trailing P/E, while MOH leads on capital efficiency and profitability with 17.2% ROIC and 13.1% gross margin. CAI currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with HSIC at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HSIC
ACTIVE
Henry Schein Inc. | D+ | 58/100 | 23.0x | 31.1% | 11.2% | +2.05% | $9.46B | Benchmark Subject |
| OSCR Oscar Health Inc. | D+ | 53/100 | — | — | -35.0% | +2.07% | $9.37B | /oscr-vs-hsic → |
| CAI Caris Life Sciences Inc. | B | 73/100 | — | — | 4.4% | -6.50% | $9.70B | /cai-vs-hsic → |
| MOH Molina Healthcare Inc | D+ | 57/100 | 22.0x | 13.1% | 17.2% | +1.79% | $10.69B | /moh-vs-hsic → |
| GRAL GRAIL Inc. | D+ | 54/100 | — | — | -18.0% | -6.74% | $6.41B | /gral-vs-hsic → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-27 • CIK 0001000228 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-27), Henry Schein Inc. (HSIC) reported GAAP revenue of $13.18B (+4.0% vs. FY2024 revenue of $12.67B , and +6.8% cumulative change since FY2023) , GAAP net income of $419.0M, operating cash flow of $712.0M, and free cash flow of $118.7M (-57.3% YoY). On the balance sheet, HSIC closed FY2025 with $11.21B in total assets against $2.89B in total debt (Altman Z-Score: 2.81, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-27 | $13.18B | $419.0M | $712.0M | $118.7M | $11.21B | $2.89B |
| FY2024 (FY) | 2024-12-28 | $12.67B | $398.0M | $848.0M | $277.7M | $10.22B | $2.42B |
| FY2023 (FY) | 2023-12-30 | $12.34B | $436.0M | $500.0M | -$55.3M | $14.81B | $3.46B |
3. HSIC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HSIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Henry Schein Inc. (NASDAQ: HSIC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $86.62 (+2.05% 1D, market cap $9.46B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, HSIC ranks #180 in composite RQD confidence.
How does HSIC compare to OSCR and CAI in the Health Care sector?
Within the Health Care sector (Medical Specialities), HSIC carries a Roarable D+ (58/100 RQD), trailing P/E of 23.0x, gross margin of 31.1%, and ROIC of 11.2%. By comparison, OSCR (Oscar Health Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.37B) and CAI (Caris Life Sciences Inc.) posts a B grade (73/100 RQD, P/E N/A, ROIC 4.4%, cap $9.70B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HSIC?
Per HSIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001000228), Henry Schein Inc. generated $13.18B in revenue (+4.0% YoY), $419.0M in net income, and $118.7M in free cash flow against $11.21B in total assets and $2.89B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HSIC trading relative to its 50-day, 200-day, and 52-week technical levels?
HSIC last traded at $86.62 (+2.05% on volume of 2,501,946 shares), positioning the stock +0.34% above its 50-day simple moving average ($86.33) and +6.71% above its 200-day simple moving average ($81.17). Across its 52-week range of $63.04 to $92.18, HSIC sits at the 80.9% percentile with a 14-day RSI of 47.5 (NEUTRAL RANGE) and an implied next-earnings move of ±4.8% ($82.46 to $90.78).
ROARABLE RATING BRIEF • RQD 58/100 (D+)
✓ SEC XBRL & RQD VERIFIED
HSIC — Henry Schein Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-27
1. Roarable Rating Brief: What This Means to a Prospective Investor
Henry Schein Inc. (HSIC) earns a live Roarable RQD composite score of 58/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $86.62 (+2.05% 1D, market capitalization $9.46B).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 11.2%, gross margin of 31.1%, operating margin of 5.0%, and free cash flow yield of 1.23%.
- Whale 13F & Options Flow (11/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (12/20) + Forensic Balance Sheet (14/20): Incorporates a 0.89x equity beta, Altman Z-Score of 2.81, Piotroski F-Score of 7/9, and Debt/Equity of 0.83x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Henry Schein Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical Specialities industry, profile. The company's market capitalization is $9.6B per the market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-27), Henry Schein Inc. (HSIC) reported $13.18B in annual revenue (up from $12.67B in FY2024, +4.0% YoY) and $419.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.34B revenue, $436.0M net income) through FY2025, HSIC scaled operating cash flow to $712.0M and free cash flow to $118.7M, backed by $11.21B in total assets against $2.89B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 58/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.23% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $63.04 – $92.18 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 23.0x trailing P/E and 9.5x EV/EBITDA against 5.0% operating margins and a 0.89x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical Specialities (Health Care), HSIC carries a macro regime beta of 0.89 and gross margin of 31.1%.
- Key Question #1: Can HSIC sustain or expand its 5.0% operating margin and 11.2% ROIC against Medical Specialities peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $13.18B and free cash flow of $118.7M, how will capital allocation balance growth reinvestment against $2.89B in total debt?
- Key Question #3: How sensitive is HSIC's 21.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.89x)?
HSIC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Henry Schein Inc. (HSIC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 22h ago
Should Value Investors Buy Henry Schein (HSIC) Stock? Yahoo Finance report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Henry Schein to Report Q3 Earnings: Here's What You Should Know TradingView report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Henry Schein (HSIC), What Is Behind The Fresh Attention Now? Yahoo Finance report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Unpacking Q2 Earnings: Henry Schein (NASDAQ:HSIC) In The Context Of Other Dental Equipment & Technology Stocks The Globe and Mail report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH TradingView • 1d ago
Henry Schein, Inc. Stock 12‑Month Price Target Cut to $97.27, Implies 16% Upside TradingView report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall Street • 1d ago
Why Henry Schein (HSIC) Is Getting Attention Now Simply Wall Street report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Henry Schein, Inc. Estimates – NASDAQ:HSIC TradingView report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
Henry Schein (HSIC) Could Be 16% Undervalued On Higher Margin Growth Story Simply Wall St report covering Henry Schein Inc. (HSIC) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
HSIC Bull vs. Bear Conversation Board — What's Your Call at $86.62?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HSIC 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $112.04 (+32.0%)
📌 Pinned Debate Forensic balance sheet scores 14 of 20 with Altman Z 2.81, Piotroski F 7/9, and Debt/Equity 0.83, supported by a 0.89 beta.
Long HSIC at $84.88 targeting $112.04. Forensic balance sheet scores 14 of 20 with Altman Z 2.81, Piotroski F 7/9, and Debt/Equity 0.83, supported by a 0.89 beta.. Institutional whale score is 11/20 and the risk/reward vs. the $68.00 52-week low is skewed heavily in favor of bulls.
CapAlloc_Nerd 🐂 BULL
@CashFlowKing Agree on the RQD 58/100 quality, though with 0.89 beta I'm scaling in with half-size at $84.88 and keeping dry powder in case we test $78.94.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $64.51 (-24.0%)
Spot @ $84.88 Fundamental Cash Engine scores only 9 of 20 with a 1.23% FCF yield against a trailing P/E of 23.
Sitting on the sidelines or leaning short HSIC above $84.88. Fundamental Cash Engine scores only 9 of 20 with a 1.23% FCF yield against a trailing P/E of 23.. Until Fundamental Cash Engine (9/20) and FCF yield (1.23%) inflect higher, upside is capped near $92.18.